Quince Therapeutics, Inc. Increase (Decrease) in Other Operating Liabilities
Quince Therapeutics, Inc. (QNCX) reported Increase (Decrease) in Other Operating Liabilities of $13.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2026-08-14
- Quince Therapeutics, Inc. increase (decrease) in other operating liabilities for the quarter ending 2026-06-30 was -$688.00K.
- Quince Therapeutics, Inc. increase (decrease) in other operating liabilities for the quarter ending 2026-03-31 was $701.00K.
- Quince Therapeutics, Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-06-30 was -$26.00K.
- Quince Therapeutics, Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-03-31 was -$1.00K.
- Quince Therapeutics, Inc. increase (decrease) in other operating liabilities for fiscal 2025 was $742.00K, a 580.73% increase from fiscal 2024.
- Quince Therapeutics, Inc. increase (decrease) in other operating liabilities for fiscal 2024 was $109.00K.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 12 month |
|---|---|---|---|
| 2026-06-30 | -$688.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $13.00K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $701.00K 10-Q · filed 2026-05-11 | ||
| 2025-12-31 | $742.00K 10-K · filed 2026-04-10 | ||
| 2025-06-30 | -$26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$27.00K 10-Q · filed 2026-08-14 | |
| 2025-03-31 | -$1.00K 10-Q · filed 2026-05-11 | ||
| 2024-12-31 | $109.00K 10-K · filed 2026-04-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |